EQS-News: GeoVax, Inc. / Key word(s): FinancialGeoVax Highlights Newly Published Independent Research Supporting Broader Filovirus Vaccine Strategies and Strategic Value of Its MVA-Based Vaccine Portfolio03.08.2026 / 15:03 CET/CESTThe issuer is solely responsible for the content of this announcement. The investigators concluded that these findings support further evaluation of existing and next-generation vaccine strategies against Bundibugyo virus and other related filoviruses. Together with the Company's Marburg virus vaccine program, these vaccine candidates comprise a differentiated filovirus vaccine portfolio built upon GeoVax's proprietary MVA platform. David A. Dodd, Chairman and Chief Executive Officer of GeoVax, commented: "Independent scientific validation plays an important role in advancing preparedness strategies for emerging infectious diseases. GeoVax was not involved in conducting the study, and the findings should not be interpreted as demonstrating efficacy of GeoVax vaccine candidates against Bundibugyo ebolavirus.